Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has maintained an Overweight rating on Supernus Pharmaceuticals (NASDAQ:SUPN) and raised the price target from $42 to $43.
November 09, 2023 | 7:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Supernus Pharmaceuticals' price target has been raised from $42 to $43 by Piper Sandler, which maintains an Overweight rating on the stock.
The news of Piper Sandler maintaining an Overweight rating on Supernus Pharmaceuticals and raising the price target is likely to be seen positively by the market. This could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100